Text Size

Improving Clinical PET/CT Image Quality in Retrospectively Reconstructed Breath-Hold Images

This study has been terminated.
(Lack of accrual)
Sponsor:
Information provided by (Responsible Party):
Memorial Sloan-Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT01109953
First received: April 20, 2010
Last updated: March 15, 2012
Last verified: March 2012
History of Changes
  Purpose

The patient has been referred for an FDG PET/CT scan. FDG is a form of sugar that contains a small amount of radioactivity; it is used to see the size and possible spread of cancer in the body.

Pictures of the body are taken on a machine called a PET/CT scanner. The purpose of this current study is to see if we, the investigators, can take clearer pictures of the tumor than we could with our routine scan method. This would allow us to better see how FDG is picked up by the tumor. PET/CT is presently one of the best tools for detecting cancer and determining its spread in the body. However, due to breathing motion, PET and CT images may become blurred and the location of the tumor on CT and PET images may not match. We have developed a new method that enables us to reduce image blurring and to measure the tumor more accurately on PET images. In this study we want to compare two kinds of images: those from the standard PET/CT scan, and the PET/CT scan pictures taken with our new method.

If successful, we may use this new method for clinical routine in the future.


Condition Intervention
Lung Cancer
 Other: Breath-Hold PET/CT image set

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Improving Clinical PET/CT Image Quality in Retrospectively Reconstructed Breath-Hold Images

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Memorial Sloan-Kettering Cancer Center:

Primary Outcome Measures:
  • To determine if our breath-hold acquisition technique can be implemented in whole-body PET/CT scans. [ Time Frame: at the time of scan ] [ Designated as safety issue: No ]
    Because PET events not satisfying the breathing amplitude selection criteria will be dropped off the final image set, it will be necessary to increase the acquisition time for the FOV's covering the thorax area from 3 min/bed to 5 min/bed to compensate for the reduction in statistics. This should result in a total increase of ~6 min for the whole body scan.


Secondary Outcome Measures:
  • To determine if whole body PET/CT improves spatial matching of PET and CT [ Time Frame: at the time of scan ] [ Designated as safety issue: No ]
    to compare image quality, blurring, PET-to-CT mis-match, and lesion SUV of the standard PET images with the breath-hold ones.


Enrollment: 6
Study Start Date: April 2010
Study Completion Date: March 2012
Primary Completion Date: March 2012 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Breath-Hold PET/CT image
In addition to the standard clinical PET/CT images, we will provide a breath-hold PET/CT image set, using the same PET data for both.
 Other: Breath-Hold PET/CT image set
In addition to the standard clinical PET/CT images, we will provide a breath-hold PET/CT image set, using the same PET data for both. In order to spatially match PET, and therefore improve attenuation correction in the PET images, we will acquire a Breath-Hold CT at 310 mA over the same region covered by PET. The normal-organ doses accumulated from the additional 30 mA CT. The patient's breathing signal during CT and the whole body PET will be recorded using a video camera and in house developed software. We will compare the clinical PET/CT and Breath-Hold PET/CT in regards to lesion detection, lesion volume, and SUV quantification.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients scheduled for whole body FDG PET/CT examination as part of their routine clinical care.

Criteria

Inclusion Criteria:

  • Participant is capable of providing written consent.
  • 18 years of age or older.
  • Patient with a known or suspected FDG-avid malignancy in the torso

Exclusion Criteria:

  • none
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01109953

Locations
United States, New York
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10065
Sponsors and Collaborators
Memorial Sloan-Kettering Cancer Center
Investigators
Principal Investigator: Heiko Schoder, MD Memorial Sloan-Kettering Cancer Center
  More Information

Additional Information:
Memorial Sloan-Kettering Cancer Center  This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party: Memorial Sloan-Kettering Cancer Center
ClinicalTrials.gov Identifier: NCT01109953     History of Changes
Other Study ID Numbers: 10-054
Study First Received: April 20, 2010
Last Updated: March 15, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by Memorial Sloan-Kettering Cancer Center:
Lung
PET/CT scan
10-054

Additional relevant MeSH terms:
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
 Neoplasms
Lung Diseases
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on May 23, 2013